BACKGROUND AND OBJECTIVES: Methylation of DNA is a common epigenetic
modification that plays an important role in the control of gene expression in mammalian …

Methylation of DNA is a biochemical modification that can influence gene expression and is
involved in inactivating one of the two X chromosomes in women. Evidence that has …

Approximately 50% of acute myeloid leukemia (AML) patients do not respond to induction
therapy (primary induction failure [PIF]) or relapse after< 6 months (early relapse [ER]). We …

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice,
With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of …

PURPOSE: 5-Aza-2′-deoxycytidine (decitabine; DAC) is a DNA hypomethylating agent that
has shown a 50% response rate in a small phase II study in elderly patients with high-risk …

The suppressor of cytokine signaling (SOCS) family of proteins has been implicated in the
negative regulation of several cytokine pathways, particularly the receptor-associated …

Aza-2′-deoxycytidine (5-AZA-CdR, decitabine), an epigenetic drug that inhibits DNA
methylation, is currently used to treat myelodysplastic syndrome (MDS), and is under …

Background DNA methylation is the addition of a methyl group to the 5 position of cytosine. It
is an epigenetic process with several effects, including chromatin structure modulation …

Prognosis in relapsed and refractory acute myeloid leukemia (R/R AML) patients is dismal,
with no satisfactory and standard salvage chemotherapy regimen. We performed a …

BACKGROUND General and site‐specific DNA methylation is associated with tumor
progression and resistance in several cancers, including chronic myelogenous leukemia …